First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. - Wikidata - awgldk - TriplyDB

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

http://www.wikidata.org/entity/Q33777877

about

IDH1 and IDH2 mutations in gliomas Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.Current treatment of low grade gliomas Adult low-grade glioma: 19-year experience at a single institution.How molecular testing can help (and hurt) in the workup of gliomas.Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors A new functional classification system (FGA/B) with prognostic value for glioma patients.What do we know about IDH1/2 mutations so far, and how do we use it?Comparison of long-term survival between temozolomide-based chemoradiotherapy and radiotherapy alone for patients with low-grade gliomas after surgical resection.Clinical implications of molecular neuropathology and biomarkers for malignant glioma.IDH mutations in human glioma Chemotherapy in glioma.Molecularly based management of gliomas in clinical practice.The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review

P2860

Q24561928-4C564AF1-7811-47A4-83A6-50974E666209 Q33399939-F30FB542-DFF7-44A8-8D53-D32BA102A1F3 Q34168829-F7037D41-C0EF-4686-83E2-369C4361B451 Q34186787-B84B1211-563D-49A4-A48B-E76FA7B6FD6B Q34224704-9F2CF84D-0333-416A-8B21-7B6B23FDFB30 Q34830708-5497182A-B5DC-4173-BFEE-E2152EBF64FA Q35183129-32E11BE5-E202-4534-9118-169D96D3AE20 Q35770275-A9302C0D-0FDB-4760-8395-EB6EBFED4108 Q35787908-0F7C5AA3-59E7-4461-BB5B-FD2342A9D272 Q36069167-CF22E09E-B403-4199-B314-1B3A193858E2 Q36288720-1D5E514C-2204-4412-BBBD-7EE10A3C24BF Q36788229-E078B8B3-F808-4FBF-A7C8-7F4BAE8F1D47 Q37194312-E0107D3C-C8CA-44B2-A8EE-C96BB2717045 Q37994631-6A5950C0-C7C5-4B41-81BA-6821DB3B6543 Q38022856-5B1376AE-25AF-4DEA-9647-67295B883852 Q38438439-B56DF3AE-6A19-48F6-AF31-FFED5D6DE196 Q38551010-66FB7F16-F907-4B2F-BA78-864E9C2AD367 Q38623610-AEF2220E-671C-49C4-A884-F31047F8C085 Q38623612-B0BFAEEE-5128-4A31-AA7B-BC8BF415EEC4 Q40291585-5A7B15A3-A1BE-4E2A-9A71-5A1151ACBBFD Q41536288-F68D4E70-CBF6-47FD-A462-FC5A4331B8DD Q42779710-EDC677EA-791A-4059-9A36-8651D46B3B66 Q45841104-322B2AFF-0FF0-41AD-A47D-5F6FA1F81F16 Q48595553-A95388B3-349F-463C-A7FA-566ED5F1DA94 Q55460949-E15DF1AB-4722-460E-BCD8-67965F2F63E2 Q58739882-0B32BA53-7B05-4F2B-9ADA-0CE0602981FE

P2860

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

http://www.wikidata.org/entity/Q33777877

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

First-line temozolomide chemot ...... stics in relation to response.

@ast

First-line temozolomide chemot ...... stics in relation to response.

@en

type

label

First-line temozolomide chemot ...... stics in relation to response.

@ast

First-line temozolomide chemot ...... stics in relation to response.

@en

prefLabel

First-line temozolomide chemot ...... stics in relation to response.

@ast

First-line temozolomide chemot ...... stics in relation to response.

@en

P1433

Q33777877-BC62266E-16A9-41AA-849F-ACCF77E9B057

P1476

Q33777877-0D1CBBF8-4F68-4C86-AE5B-E01719676239

P2093

Q33777877-01137F72-AB2A-4F38-9F3D-6B0711088835

Q33777877-05714183-B6AE-4D22-9A62-1817A06FAC62

Q33777877-065F2C24-E5FC-4B6E-BA2F-45A07082F35A

Q33777877-0943E16C-4EE0-4FD0-AF57-161601C9FE12

Q33777877-0F2AF82F-5AE6-414C-9765-3E4BB87602DB

Q33777877-128C5497-3026-478B-A893-E366F744D06A

Q33777877-15F59632-DF38-47A6-B52E-42BDE34A3863

Q33777877-1D8FF072-AEA6-43B2-8776-88F0BB94D921

Q33777877-3778189A-ED45-44CD-ABCA-66E70AF73B5C

Q33777877-5564A102-C393-41A8-BED5-FD688198A838

P2860

Q33777877-0B1AE0AE-8C6B-4129-904D-ECA036826A51

Q33777877-0CF0333A-0BB9-45DA-B426-4F66CBA41033

Q33777877-1725C343-00D9-4BB3-BAA0-5FBD92FCA849

Q33777877-179F0F0E-F142-46A4-9BE9-7507B0FC4193

Q33777877-183ABF93-15D9-4F3D-BEB2-4CFAEEF4DA15

Q33777877-1E2DC873-7075-459B-ADA9-66A9B14EDE20

Q33777877-21836523-FDBF-4493-8259-F203DE3B8A86

Q33777877-32CFE3C1-188B-45A4-81DB-B900F401AD6A

Q33777877-3489C230-88B8-4F51-88B3-0CAFED362F22

Q33777877-34ECAF99-06C2-44C7-97D8-272C8FE49D3E

P304

Q33777877-3D96EA63-D2BB-4D92-AE8C-237781280809

P31

Q33777877-42476C25-C901-40A7-8938-1DC09C010C09

P356

Q33777877-CDC3BF5C-6419-4340-85CC-76DDB1600357

P433

Q33777877-5C88DF5D-2F9E-420A-AE36-C16DB4496902

P478

Q33777877-CD2F2709-5A93-40F4-983E-ABE992A10559

P50

Q33777877-CBDA9721-8FFF-482C-9A79-C4127025218A

P577

Q33777877-4C0718DA-3F61-46AD-8001-79DC38D9BF89

P5875

Q33777877-8AFC8410-3E3E-44AB-855E-A5723E5DFB06

P698

Q33777877-2C121C68-0716-4825-B553-126910DD22E6

P921

Q33777877-35FC8323-8D11-4A37-87B3-87C5A3078FE6

Q33777877-F0E8E28E-209C-4D8B-BA5C-5F0AC5762E01

P932

Q33777877-F7B5B0CC-10E9-4E4E-A6A5-ED7FDD633818

P356

P1433

P1476

First-line temozolomide chemot ...... stics in relation to response.

@en

P2093

Bernard A Zonnenberg

http://www.w3.org/2001/XMLSchema#string

Bronno van der Holt

http://www.w3.org/2001/XMLSchema#string

Chris B L Zonnenberg

http://www.w3.org/2001/XMLSchema#string

Dutch Society for Neuro-Oncology

http://www.w3.org/2001/XMLSchema#string

Floris H Groenendijk

http://www.w3.org/2001/XMLSchema#string

Hendrikus J Dubbink

http://www.w3.org/2001/XMLSchema#string

Irene van Heuvel

http://www.w3.org/2001/XMLSchema#string

Jacoline E C Bromberg

http://www.w3.org/2001/XMLSchema#string

Johan M Kros

http://www.w3.org/2001/XMLSchema#string

Johanna M M Gijtenbeek

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

IDH1 and IDH2 mutations in gliomas

MGMT gene silencing and benefit from temozolomide in glioblastoma.

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Outcome in adult low-grade glioma: the impact of prognostic factors and treatment.

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Determination of the molecular relationship between multiple tumors within one patient is of clinical importance.

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

P304

235-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ177

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Mathilde Kouwenhoven

P577

2010-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49701560

http://www.w3.org/2001/XMLSchema#string

P698

21177338

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3064627

http://www.w3.org/2001/XMLSchema#string